Balancing an Innovative Biotechnology Company’s Oncology Portfolio
A US-based biotech company required support to identify, evaluate and prioritize novel immunotherapies and targeted oncology drug candidates to supplement its clinical pipeline.
Guided by a search strategy developed with the company’s leadership, Shift Health identified a list of approximately 2,000 products of interest from a proprietary database of more than 60,000 molecules. We then prioritized subsequent search criteria and applied a combination of manual screens and semi-automated algorithms to create shortlists of interest. Through rigorous review, Shift Health assessed the technical and commercial merits of approximately 90 assets to prioritize 28 in-licensing targets.
The final list of products was enthusiastically approved by the company’s leadership team and led to discussion with current owners of several identified assets.